Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Benefits Of Grapefruit

Editorials Respond To Selection Of Sotomayor As Supreme Court Nominee
Several newspapers recently published editorials on President Obama"s nomination of Judge Sonia Sotomayor to the Supreme Court. Summaries appear below.~ Boston Globe: "Some liberal activists hoped that Obama would seek a firebrand to counter [Supreme Court Justice] Antonin Scalia, the darling of the right," but "Sotomayor has made her reputation not on hot-button social issues but on matters ranging from environmental regulation to the baseball business," a Globe editorial states. It adds that while Sotomayor "presumably shares Obama"s support for abortion rights, she upheld the Bush administration"s restrictions on family-planning activities" by international groups that received U.S. funding. Now, "conservative groups have seized upon an offhand remark in 2005" when she described the "federal appeals courts as the place "where policy is made" ... as evidence that Sotomayor would legislate from the bench," the editorial states, adding. "The attack is disingenuous." The editorial concludes, "Short of any unexpected revelations about her record or her philosophy, though, the Senate should confirm Sonia Sotomayor," adding that in addition to her "intriguing" personal background she "also has the experience to make an excellent Supreme Court Justice" (Boston Globe, 5/27).~ Chicago Tribune: Sotomayor "has to bring more than diversity to the court," a Tribune editorial states, adding that the "evidence so far suggests that she is up to the job." One "would expect a nominee chosen by Obama to be on the liberal side of the judicial spectrum," but some of her rulings "suggest otherwise," according to the editorial. While Sotomayor "has stressed that the "duty of a judge is to follow the law, not to question its plain terms,"" on the bench, "she ruled against an abortion-rights group challenging" the Bush administration"s "global gag rule," the editorial notes, among other rulings that "could be characterized as "conservative decisions"." However, "the point is not that she"s a closet conservative -- it"s that ideology didn"t seem to determine her decisions," according to the editorial. The "Senate has a responsibility to undertake a thorough examination of her record and her thinking," the editorial states, concluding, "But for now, it looks as though her critics have a tough task ahead of them" (Chicago Tribune, 5/27).~ Los Angeles Times: "Sotomayor doesn"t possess the political experience that would be brought to the court"s cloistered chambers by Michigan Gov. Jennifer Granholm (D) or Homeland Security Secretary Janet Napolitano," but "she satisfies Obama"s other criteria: experience, erudition and, as he put it, "a common touch and a sense of compassion, an understanding of how the world works and how ordinary people live,"" a Times editorial states. Sotomayor"s "experiences as a Latina raised in a housing project who went on to excel at Princeton and Yale don"t in themselves qualify her for the court," but these facts do "complement her sterling credentials and equip her with perspectives that could illuminate legal issues that come before her," the editorial continues. Senate Republicans "should accord her the same respect [they] demanded for Bush"s nominees and end the tiresome tit-for-tat that has cheapened the confirmation of federal judges and deprived the bench of some of the nation"s most capable legal minds," the editorial concludes (Los Angeles Times, 5/27).~ Philadelphia Inquirer: "Sotomayor would bring to the court a diversity it has lacked for most of its history," an Inquirer editorial states. Although "[c]onservatives want to make an issue out of President Obama"s search for "empathy" in a nominee" and "criticize Sotomayor for a speech in 2001 in which she said that being a woman of color affects her decisions," neither comment "is sinister nor shocking," according to the editorial. It concludes, "The Senate has a duty to examine Sotomayor"s qualifications rigorously and fairly. But she appears to have the experience and the
generic viagra online
Wellcome Trust To Give $50M To Boost Health Research In Africa
The Wellcome Trust on Thursday pledged 30 million pounds or about $50 million to support health research at more than 50 African institutions, Nature reports (Nayar, 7/1).
News of the day
PeriCor Therapeutics Reports Positive Preclinical Results Of GP531 At The European Heart Failure Congress In Nice
PeriCor Therapeutics, Inc. announced that positive preclinical results of its novel cardioprotective agent, GP531, were reported in a poster presentation by Hani N. Sabbah, Ph.D., at the European Heart Failure Congress 2009 in Nice, France. The study was funded by PeriCor Therapeutics, Inc. and conducted by Dr. Sabbah and colleagues at the Division of Cardiovascular Medicine of the Henry Ford Health System, Detroit, Michigan. GP531 is an investigational drug under development by PeriCor Therapeutics under an Investigational New Drug (IND) application.
Nutrition

FDA Appointed Arthritis Advisory Committee Recommends U.S. Food And Drug Administration Approval For KRYSTEXXA(TM) For Refractory Chronic Gout

Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced that the Arthritis Advisory Committee appointed by the U.S. Food and Drug Administration (FDA) recommended by a vote of 14 to 1 that KRYSTEXXA(TM) (pegloticase), a biologic PEGylated uricase enzyme, be granted marketing approval by the FDA for the treatment of refractory chronic gout. Refractory chronic gout or treatment failure gout (TFG) is gout in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with conventional urate-lowering therapy at the maximum medically appropriate dose or for whom conventional urate-lowering therapy is contraindicated. The current target Prescription Drug User Fee (PDUFA) action date for the FDA"s decision as to whether to grant marketing approval for KRYSTEXXA is August 1, 2009. "We are very pleased with the Advisory Committee"s recommendation, which supports our belief that KRYSTEXXA has a favorable risk to benefit profile in patients suffering from TFG," said Paul Hamelin, President of Savient Pharmaceuticals, Inc. "KRYSTEXXA has the potential to provide an important new treatment option for patients with TFG, who currently have no other available treatment options, and many of whom suffer from serious pain and disability." The Advisory Committee"s recommendation, although not binding, will be considered by the FDA in its review of the Biologics License Application that Savient has submitted for KRYSTEXXA. ABOUT SAVIENT PHARMACEUTICALS, INC. Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and marketing pharmaceutical products that target unmet medical needs in both niche and broader specialty markets. Savient is currently developing one product: KRYSTEXXA(TM) (pegloticase) as a therapy for patients with treatment failure gout, to control hyperuricemia and to manage the signs and symptoms of gout. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, formerly referred to as Puricase(R), from Duke University and Mountain View Pharmaceuticals, Inc. Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the U.S. FORWARD LOOKING LANGUAGE All statements other than statements of historical facts included in this press release are forward-looking statements that are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such statements. These risks, trends and uncertainties are in some instances beyond our control. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding the efficacy and safety of KRYSTEXXA(TM) (pegloticase), our BLA filing with the FDA, the Advisory Committee, approval of the BLA, preparation for commercialization of KRYSTEXXA, and the market for KRYSTEXXA, are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on our assessment and interpretation of the currently available data and information, our Phase 3 clinical data and on current expectations, assumptions, estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate. Important factors that may affect our ability to achieve the matters addressed in these forward-looking statements include, but are not limited to, the possibility that the FDA may not approve our BLA for KRYSTEXXA, notwithstanding the recommendation of the Advisory Committee; any delay or failure by us in completing the development of KRYSTEXXA; varying interpretations of our clinical and CMC data by the FDA; difficulties in obtaining financing; potential development of alternative or more effective products by competitors; reliance on third parties to manufacture, market and distribute many of our products; economic, political and other risks associated with foreign operations; risks of maintaining protection for our intellectual property; risks of an adverse determination in intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical industry and other important factors set forth more fully in our reports filed with the Securities and Exchange Commission, to which investors are referred for further information. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements, which speak only as of the date of publication of this press release to shareholders. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. We do not have a policy of updating or revising forward-looking statements and, except as required by law, assume no obligation to update any forward-looking statements. Savient Pharmaceuticals, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009